Technology | Population Health | April 23, 2015

Philips Introduces Predictive Analytics for Population Health Management

CareSage combines actionable insights with wearable medical alert devices to help reduce avoidable hospitalizations of elderly patients, keeping them at home and independent

April 23, 2015 — Philips introduced CareSage at HIMSS 2015, which is new predictive analytics engine that enables health systems to better monitor and care for elderly patients by combining actionable insights with wearable devices and monitoring. CareSage provides analysis of real-time and historical data from health care providers and Philips Lifeline, to proactively identify patients most likely to have health issues so clinicians can intervene before problems occur, helping patients stay healthier and reduce avoidable hospitalizations.

CareSage is the latest innovation being built on the Philips HealthSuite Digital Platform, an open cloud-based platform that supports the secure collection and analysis of health and lifestyle data from multiple sources and devices. Designed to support population health management, CareSage utilizes Philips Lifeline’s AutoAlert technology and wealth of aging and health data to focus on senior patients when they return home after a hospital visit or home health care period.

“Coming home after a hospital stay is a relief for seniors, but it also comes with potential risks. By reviewing data from CareSage’s analytics and our wearable medical alert devices, health systems can predict when their at-home patients are likely to be hospitalized and intervene in advance,” said Kimberly O’Loughlin, senior vice president and general manager of home monitoring, Philips. “CareSage is another example of Philips’ commitment to connected health; leveraging data, analytics and our 24x7 service monitoring capabilities to help provide health systems with the right data at the right time to help deliver care for a wide range of patient populations.”
 
Today, seniors use more health care resources per capita than any other group, and two-thirds of Medicare recipients are dealing with more than one chronic condition. Poor transitions in care are a key cause of unnecessary readmissions, emergency department visits and hospitalizations for seniors, which lead to both health and cost concerns. Health systems are looking to provide better outcomes at lower costs by extending care into the home, where many seniors’ health events occur. At the same time, while fewer than half of people who own wearable devices and fitness trackers actually use them every day, seniors have been active consumers of wearables for years in the form of medical alert services. When combined with predictive analytics, wearables for seniors can have a dramatic impact in proactively managing their health.
 
“More than half of frail and elderly patients are discharged without any long-term monitoring, leaving them cut off from their care while at home. Staying connected with these patients in between check-ups can help keep them healthy and help prevent events that could send them back to the hospital, which is our ultimate goal in patient care,” said Michael Hamaker, president, WellSpan VNA Home Care.
 
CareSage’s combines predictive analytics and senior-friendly home monitoring management and service tools already actively used by many consumers. Leveraging CareSage, health systems may be able to provide better preventative care and care coordination; increase patient satisfaction and improve quality of life issues; reduce long-term (beyond 30 days) avoidable readmissions; and improve health outcomes and cost savings.
 
Philips Lifeline is partnering with health systems to develop additional programs and applications for the predictive analytics engine.
 
For more information: www.healthcare.philips.com
 

Related Content

he U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption (IDE) application to start a U.S. early feasibility study (EFS) of its total artificial heart.
News | Heart Failure | February 12, 2020
February 12, 2020 — The U.S.
 Revivant TC
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less
 impulse dynamics Optimizer for Heart failure.
News | Heart Failure | December 12, 2019
December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System
The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA
News | Heart Failure | November 21, 2019
November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment
Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019
November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of
The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Overlay Init